Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-23-004238
Filing Date
2023-02-07
Accepted
2023-02-07 18:55:55
Documents
1
Period of Report
2023-02-06

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5961
  Complete submission text file 0000899243-23-004238.txt   7698
Mailing Address C/O CASCADIAN THERAPEUTICS, INC. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
Myers Scott Dunseth (Reporting) CIK: 0001356256 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36483 | Film No.: 23596573

Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Issuer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8071 Services-Medical Laboratories